Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
New UCLA study finds that oxidized lipids may also contribute to pulmonary hypertension

New UCLA study finds that oxidized lipids may also contribute to pulmonary hypertension

Speckle tracking data shows promise in right ventricular assessment

Speckle tracking data shows promise in right ventricular assessment

Paediatric PAH treatment goals identified

Paediatric PAH treatment goals identified

Mortality predictors REVEALed for PAH in systemic sclerosis

Mortality predictors REVEALed for PAH in systemic sclerosis

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

PAH disease burden ‘significant’

PAH disease burden ‘significant’

CHEST guideline released for PAH

CHEST guideline released for PAH

Haemodynamic exercise variables “important” for PAH prognostication

Haemodynamic exercise variables “important” for PAH prognostication

Prevalence of pulmonary arterial hypertension characterised in CHD patients

Prevalence of pulmonary arterial hypertension characterised in CHD patients

Renal dysfunction affects NT-proBNP predictive thresholds in pulmonary hypertension

Renal dysfunction affects NT-proBNP predictive thresholds in pulmonary hypertension

Inotropic agents support epoprostenol initiation in severe PAH

Inotropic agents support epoprostenol initiation in severe PAH

PAH risk factors identified for systemic sclerosis patients

PAH risk factors identified for systemic sclerosis patients

Triple therapy shows promise for severe PAH

Triple therapy shows promise for severe PAH

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

Japanese PAH patient prognosis ‘good’

Japanese PAH patient prognosis ‘good’

ECG abnormalities progress during pulmonary arterial hypertension course

ECG abnormalities progress during pulmonary arterial hypertension course

Research opens door to new direction of PAH treatment

Research opens door to new direction of PAH treatment

Special publication details breakthrough research on causes of vascular disease

Special publication details breakthrough research on causes of vascular disease

Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners

Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners